With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

PRESS RELEASE FROM THE MINISTRY OF HEALTH AND HUMAN SERVICES Cockburn Town, Turks and Caicos Islands, 2nd May 2025: In response to a U.S. Food and Drug Administration (FDA) alert relating to the ...

Her Excellency, Dileeni Daniel-Selvaratnam chaired the 5th meeting of Cabinet held on Wednesday April 2, 2025, at the Hon ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...